Blueprint drug succeeds in rare disease study important to its market prospects

A drug developed by Blueprint Medicines helped reduce symptoms of patients with a slow-moving, early form of the rare disease systemic mastocytosis in a Phase 2 trial, positioning the company to ask for regulatory approval later this year.